Pieris Pharmaceuticals Investor Presentation — August 2019

Document content

AUGUST 2019Forward Looking Statements

This presentation contains forward -looking statements asthat term isdefined inSection 27AoftheSecurities Actof1933 and

Section 21EoftheSecurities Exchange Actof1934. Statements inthispress release that arenotpurely historical areforward -

looking statements .Such forward -looking statements include, among other things, references tonovel technologies andmethods

andourbusiness andproduct development plans, including theadvancement ofourproprietary andco-development programs

intoandthrough theclinic .Actual results could differ from those projected inanyforward -looking statements duetonumerous

factors .Such factors include, among others, ourability toraise theadditional funding wewillneed tocontinue topursue our

business andproduct development plans ;theinherent uncertainties associated with developing new products ortechnologies and

operating asadevelopment stage company ;ourability todevelop, complete clinical trials for,obtain approvals forand

commercialize anyofourproduct candidates, including ourability torecruit and enroll patients inourstudies ;ourability to

address therequests oftheFDA; competition intheindustry inwhich weoperate andmarket conditions .These forward -looking

statements aremade asofthedate ofthispress release, andweassume noobligation toupdate theforward -looking statements,

ortoupdate thereasons why actual results could differ from those projected intheforward -looking statements, except asrequired

bylaw.Investors should consult alloftheinformation setforth herein andshould also refer totheriskfactor disclosure setforth in

thereports and other documents wefilewith theSEC available atwww .sec.gov, including without limitation theCompany's

Annual Report onForm 10-Kforthefiscal year ended December 31,2018 andtheCompany's Quarterly Reports onForm 10-Q.

2What are Anticalin®proteins?

A Novel Therapeutic Class with

Favorable Drug -Like Properties

•Derived from lipocalins (human

extracellular binding proteins)

•TLC and NGAL lipocalins used as

“templates” for drug development

•Engineerable binding pocket for

robust target engagement

•Monomeric, monovalent, small size (~18 kDavs 150kDa mAbs )

•Can be formulated for inhalable delivery

•Can be formatted into novel bi/multispecific constructs

•Broad IP positionUnderpinned by a Powerful

Drug Discovery Platform

Preview truncated — download the full document for the complete content.